NSRX AMEX
Nasus Pharma Ltd.
1W: -9.0%
1M: -4.5%
3M: -48.9%
YTD: -63.8%
$2.70
+0.00 (+0.00%)
Weekly Expected Move ±23.8%
$2
$2
$3
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$23.3M
52W Range1.98-9.99
Volume17,951
Avg Volume213,591
Beta3.89
Dividend—
Analyst Ratings
Company Info
CEODan Teleman
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2025-08-13
Websitenasuspharma.com
Yigal Alon 65
Tel Aviv 6744317
IL
Tel Aviv 6744317
IL
97235736632
About Nasus Pharma Ltd.
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Teleman Dan Benjamin | P-Purchase | 2,900 | $3.76 | 2026-04-22 |
| Teleman Dan Benjamin | P-Purchase | 15,000 | $2.04 | 2026-03-31 |
| Rubin Eyal | 40,549 | $7.56 | 2026-03-27 | |
| Teleman Dan Benjamin | 0 | — | 2026-03-18 | |
| Gilboa Udi | 0 | — | 2026-03-18 |